Zhao Ying Y, Mehra Reena
Sleep Care Solutions, 1835 Yonge Street, Suite 303, Toronto, Ontario, M4S 1X8, Canada.
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Curr Heart Fail Rep. 2017 Aug;14(4):284-300. doi: 10.1007/s11897-017-0339-7.
Sleep-disordered breathing (SDB) is highly prevalent in heart failure (HF) and may confer significant stress to the cardiovascular system and increases the risk for future cardiovascular events. The present review will provide updates on the current understanding of the relationship of SDB and common HF biomarkers and the effect of positive airway pressure therapy on these biomarkers, with particular emphasis in patients with coexisting SDB and HF.
Prior studies have examined the relationship between HF biomarkers and SDB, and the effect of SDB treatment on these biomarkers, with less data available in the context of coexisting SDB and HF. Overall, however, the association of SDB and circulating biomarkers has been inconsistent. Further research is needed to elucidate the relationship between biomarkers and SDB in HF, to evaluate the clinical utility of biomarkers over standard methods in large, prospective studies and also to assess the impact of treatment of SDB on these biomarkers in HF via interventional studies.
睡眠呼吸障碍（SDB）在心力衰竭（HF）中极为常见，可能给心血管系统带来巨大压力，并增加未来发生心血管事件的风险。本综述将提供有关SDB与常见HF生物标志物关系的最新认识，以及气道正压通气治疗对这些生物标志物的影响，尤其着重于同时存在SDB和HF的患者。
既往研究探讨了HF生物标志物与SDB之间的关系，以及SDB治疗对这些生物标志物的影响，但在同时存在SDB和HF的情况下，可用数据较少。然而总体而言，SDB与循环生物标志物之间的关联并不一致。需要进一步研究以阐明HF中生物标志物与SDB之间的关系，在大型前瞻性研究中评估生物标志物相对于标准方法的临床实用性，并通过干预性研究评估SDB治疗对HF中这些生物标志物的影响。
